Assignee
NOVAVAX INC
US53 patents
Top patents by PatentIndex Score
US10953089B1Mar 23, 2021
Coronavirus vaccine formulations
NOVAVAX INC99 citations98
US5629021AMay 13, 1997
Micellar nanoparticles
NOVAVAX INC277 citations98
US5547677AAug 20, 1996
Antimicrobial oil-in-water emulsions
NOVAVAX INC144 citations98
US5618840AApr 8, 1997
Antibacterial oil-in-water emulsions
NOVAVAX INC102 citations97
US5549901AAug 27, 1996
Antimicrobial oil-in-water emulsions
NOVAVAX INC140 citations97
US7763450B2Jul 27, 2010
Functional influenza virus-like particles (VLPs)
NOVAVAX INC48 citations96
US6387373B1May 14, 2002
Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
NOVAVAX INC74 citations96
US5795582AAug 18, 1998
Adjuvant properties of poly (amidoamine) dendrimers
NOVAVAX INC63 citations96
US5730989AMar 24, 1998
Oral vaccine against gram negative bacterial infection
NOVAVAX INC64 citations96
US5700679ADec 23, 1997
Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
NOVAVAX INC86 citations96
US5662957ASep 2, 1997
Oil containing lipid vesicles with marine applications
NOVAVAX INC67 citations96
US10022437B2Jul 17, 2018
Modified RSV F proteins and methods of their use
NOVAVAX INC22 citations94
US10426829B2Oct 1, 2019
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC17 citations93
US9675685B2Jun 13, 2017
Modified RSV F proteins and methods of their use
NOVAVAX INC11 citations92
US9180180B2Nov 10, 2015
Functional influenza virus-like particles (VLPs)
NOVAVAX INC15 citations92
US9050290B2Jun 9, 2015
Functional influenza virus like particles (VLPs)
NOVAVAX INC18 citations92
US11541112B2Jan 3, 2023
Coronavirus vaccine formulations
NOVAVAX INC5 citations85
US11253585B2Feb 22, 2022
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC8 citations84
US11253586B2Feb 22, 2022
Coronavirus vaccine formulations
NOVAVAX INC4 citations84
US11052146B2Jul 6, 2021
Modified RSV F proteins and methods of their use
NOVAVAX INC3 citations84
US9731000B2Aug 15, 2017
Modified RSV F proteins and methods of their use
NOVAVAX INC7 citations84
US9717786B2Aug 1, 2017
Modified RSV F proteins and methods of their use
NOVAVAX INC7 citations84
US9937253B2Apr 10, 2018
Functional influenza virus-like particles (VLPS)
NOVAVAX INC5 citations83
US9694066B2Jul 4, 2017
Functional influenza virus like particles (VLPs)
NOVAVAX INC6 citations83
US9623104B2Apr 18, 2017
Functional influenza virus-like particles (VLPS)
NOVAVAX INC7 citations83
US9474799B2Oct 25, 2016
Functional influenza virus-like particles (VLPS)
NOVAVAX INC8 citations83
US7041500B2May 9, 2006
Insect cell line
NOVAVAX INC12 citations82
US9464276B2Oct 11, 2016
Highly efficient influenza matrix (M1) proteins
NOVAVAX INC8 citations81
US7393541B2Jul 1, 2008
Mycobacterial vaccine
NOVAVAX INC10 citations78
US12357684B2Jul 15, 2025
Modified RSV F proteins and methods of their use
NOVAVAX INC2 citations74
US11896664B2Feb 13, 2024
Corona virus vaccine formulations
NOVAVAX INC2 citations73
US11446374B2Sep 20, 2022
Modified RSV F proteins and methods of their use
NOVAVAX INC5 citations73
US6034073AMar 7, 2000
Solvent detergent emulsions having antiviral activity
NOVAVAX INC10 citations73
US10188723B2Jan 29, 2019
Functional influenza virus like particles (VLPs)
NOVAVAX INC2 citations72
US9956280B2May 1, 2018
Functional influenza virus-like particles (VLPs)
NOVAVAX INC3 citations72
US11364294B2Jun 21, 2022
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC2 citations71
US11278612B2Mar 22, 2022
Multivalent influenza nanoparticle vaccines
NOVAVAX INC3 citations68
US6060066AMay 9, 2000
Method for treating tumors with a toxin
NOVAVAX INC5 citations68
US9381239B2Jul 5, 2016
VLPS derived from cells that do not express a viral matrix or core protein
NOVAVAX INC2 citations63
US12491241B2Dec 9, 2025
Coronavirus vaccine formulations
NOVAVAX INC0 citations62
US12472246B2Nov 18, 2025
Coronavirus vaccine formulations
NOVAVAX INC0 citations62
US12257297B2Mar 25, 2025
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC0 citations61
US11938179B2Mar 26, 2024
Methods and compositions for inducing immune responses against Clostridium difficile
NOVAVAX INC0 citations61
US11123419B2Sep 21, 2021
Methods and compositions for inducing immune responses against Clostridium difficile
NOVAVAX INC1 citations61
US10751410B2Aug 25, 2020
Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
NOVAVAX INC1 citations61
US9951317B2Apr 24, 2018
Highly efficient influenza matrix (M1) proteins
NOVAVAX INC1 citations60
US12083228B2Sep 10, 2024
Methods and compositions for treating respiratory disease
NOVAVAX INC1 citations59
US11896662B2Feb 13, 2024
Multivalent influenza nanoparticle vaccines
NOVAVAX INC0 citations58
US10086065B2Oct 2, 2018
Rabies glycoprotein virus-like particles (VLPS)
NOVAVAX INC0 citations52
US10729760B2Aug 4, 2020
Functional influenza virus like particles (VLPs)
NOVAVAX INC0 citations51
Showing the top 50 of 53 patents by PatentIndex Score.